CoChat

N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling

Open access
Park, Taeyeop, Chen, Huazhen, Kevala, Karl, Lee, Ji-Won, Kim, Hee-Yong · 2016 · Journal of Neuroinflammation

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

BACKGROUND: Brain inflammation has been implicated as a critical mechanism responsible for the progression of neurodegeneration and characterized by glial cell activation accompanied by production of inflammation-related cytokines and chemokines. Growing evidence also suggests that metabolites derived from docosahexaenoic acid (DHA) have anti-inflammatory and pro-resolving effects; however, the possible role of N-docosahexaenoylethanolamine (synaptamide), an endogenous neurogenic and synaptogenic metabolite of DHA, in inflammation, is largely unknown. (The term "synaptamide" instead of "DHEA" was used for N-docosahexaenoylethanolamine since DHEA is a widely used and accepted term for the steroid, dehydroepiandrosterone.) In the present study, we tested this possibility using a lipopolysaccharide (LPS)-induced neuroinflammation model both in vitro and in vivo. METHODS: For in vitro studies, we used P3 primary rat microglia and immortalized murine microglia cells (BV2) to assess synaptamide effects on LPS-induced cytokine/chemokine/iNOS (inducible nitric oxide synthase) expression by quantitative PCR (qPCR) and enzyme-linked immunosorbent assay (ELISA). To evaluate in vivo effects, mice were intraperitoneally (i.p.) injected with LPS followed by synaptamide, and expression of proinflammatory mediators was measured by qPCR and western blot analysis. Activation of microglia and astrocyte in the brain was examined by Iba-1 and GFAP immunostaining. RESULTS: Synaptamide significantly reduced LPS-induced production of TNF-α and NO in cultured microglia cells. Synaptamide increased intracellular cAMP levels, phosphorylation of PKA, and phosphorylation of CREB but suppressed LPS-induced nuclear translocation of NF-κB p65. Conversely, adenylyl cyclase or PKA inhibitors abolished the synaptamide effect on p65 translocation as well as TNF-α and iNOS expression. Administration of synaptamide following LPS injection (i.p.) significantly reduced neuroinflammatory responses, such as microglia activation and mRNA expression of inflammatory cytokines, chemokine, and iNOS in the brain. CONCLUSIONS: DHA-derived synaptamide is a potent suppressor of neuroinflammation in an LPS-induced model, by enhancing cAMP/PKA signaling and inhibiting NF-κB activation. The anti-inflammatory capability of synaptamide may provide a new therapeutic avenue to ameliorate the inflammation-associated neurodegenerative conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-016-0751-z

Cites

Statistics

Figures

Fig. 1 Inhibitory effect of synaptamide on LPS-induced expression of TNF-α and iNOS in microglia cells. Primary rat microglia cells were incubated with LPS (100 ng/mL) and/or synaptamide at the indicated concentration. Synaptamide was added immediately after LPS exposure. Levels of TNF-α (a) and iNOS (b) mRNA were determined by qPCR after 1 h incubation. After 24 h, accumulated levels of TNF-α (c) and nitric oxide (d) in the media were measured by ELISA and Griess reaction. The data represent the mean ± SEM at least three independent experiments. Means designated with the same letter are not significantly different. One-way ANOVA followed by Tukey’s post hoc test (Prism Software, SigmaStat)
Fig. 1 Inhibitory effect of synaptamide on LPS-induced expression of TNF-α and iNOS in microglia cells. Primary rat microglia cells were incubated with LPS (100 ng/mL) and/or synaptamide at the indicated concentration. Synaptamide was added immediately after LPS exposure. Levels of TNF-α (a) and iNOS (b) mRNA were determined by qPCR after 1 h incubation. After 24 h, accumulated levels of TNF-α (c) and nitric oxide (d) in the media were measured by ELISA and Griess reaction. The data represent the mean ± SEM at least three independent experiments. Means designated with the same letter are not significantly different. One-way ANOVA followed by Tukey’s post hoc test (Prism Software, SigmaStat)CC BY · PubMed Central
Fig. 2 Suppression of LPS-induced TNF-α and iNOS expression specific to synaptamide. Cells were incubated with LPS (100 ng/mL) and acylethanolamides at 10 nM. Acylethanolamides were added immediately after LPS exposure. Levels of TNF-α and iNOS (a, b; rat primary microglial cell, c, d; BV2 murine microglial cell) mRNA were determined by qPCR after 1 h incubation. The data represent the mean ± SEM at least three independent experiments. Means designated with the same letter are not significantly different
Fig. 2 Suppression of LPS-induced TNF-α and iNOS expression specific to synaptamide. Cells were incubated with LPS (100 ng/mL) and acylethanolamides at 10 nM. Acylethanolamides were added immediately after LPS exposure. Levels of TNF-α and iNOS (a, b; rat primary microglial cell, c, d; BV2 murine microglial cell) mRNA were determined by qPCR after 1 h incubation. The data represent the mean ± SEM at least three independent experiments. Means designated with the same letter are not significantly differentCC BY · PubMed Central
Fig. 3 Involvement of cAMP/PKA signaling in the suppression of LPS-induced TNF-α expression by synaptamide. Microglia cells were incubated with LPS (100 ng/mL) and 10 nM synaptamide, and levels of TNF-α and iNOS mRNA were determined by qPCR at 1 h after incubation. 5-, 12-, 15-LOX inhibitor (2-TEDC, 10 μM); COX inhibitor (Indo, 10 μM); P450 inhibitor (KTZ, 10 μM) (a); adenylyl cyclase inhibitor (SQ 22536, 10 μM); and PKA inhibitor (H-89, 10 μM) (b, c) were added 30 min prior to LPS treatment. BV2 murine microglia cells were transfeted with PKA siRNA or scrambled control RNA for 48 h prior to the treatment with LPS (100 ng/mL) and synaptamide (10 nM) for 1 h (d, e). Successful knockdown of PKA expression is indicated in the inset. PKA primary rat microglia (f, upper) and BV2 (f, bottom) cells were treated with synaptamide (1–100 nM) or forskolin (For, 10 μM) as a positive control for 15 min, and cAMP levels were measured. BV2 cells were incubated with synaptamide at the indicated concentration for 30 min and subjected to immunoblot analysis using antibodies that specifically recognize phosphorylated and non-phosphorylated PKA, CREB (g). Graph values are mean ± SEM of protein levels of p-PKA/p-CREB relative to PKA/CREB, respectively (n = 3). Means designated with the same letter are not significantly different
Fig. 3 Involvement of cAMP/PKA signaling in the suppression of LPS-induced TNF-α expression by synaptamide. Microglia cells were incubated with LPS (100 ng/mL) and 10 nM synaptamide, and levels of TNF-α and iNOS mRNA were determined by qPCR at 1 h after incubation. 5-, 12-, 15-LOX inhibitor (2-TEDC, 10 μM); COX inhibitor (Indo, 10 μM); P450 inhibitor (KTZ, 10 μM) (a); adenylyl cyclase inhibitor (SQ 22536, 10 μM); and PKA inhibitor (H-89, 10 μM) (b, c) were added 30 min prior to LPS treatment. BV2 murine microglia cells were transfeted with PKA siRNA or scrambled control RNA for 48 h prior to the treatment with LPS (100 ng/mL) and synaptamide (10 nM) for 1 h (d, e). Successful knockdown of PKA expression is indicated in the inset. PKA primary rat microglia (f, upper) and BV2 (f, bottom) cells were treated with synaptamide (1–100 nM) or forskolin (For, 10 μM) as a positive control for 15 min, and cAMP levels were measured. BV2 cells were incubated with synaptamide at the indicated concentration for 30 min and subjected to immunoblot analysis using antibodies that specifically recognize phosphorylated and non-phosphorylated PKA, CREB (g). Graph values are mean ± SEM of protein levels of p-PKA/p-CREB relative to PKA/CREB, respectively (n = 3). Means designated with the same letter are not significantly differentCC BY · PubMed Central
Fig. 4 Inhibition of LPS-induced p65 translocation by synaptamide. BV2 murine microglia cells were incubated with LPS (100 ng/mL) with or without synaptamide (10 nM) and OEA (10 nM) for 30 min. Adenylyl cyclase inhibitor (SQ 22536, 10 μM) and PKA inhibitor (H-89, 10 μM) were added 30 min prior to LPS/synaptamide treatment. Translocation of p65 was determined by immunocytochemistry (red, Alexa Fluor 588; blue, DAPI) (a). Nuclear levels of p65 were determined by immunoblot analysis. α-Tublin and lamin A/C were used as internal controls for cytosolic and nuclear fractions (b). Densitometric analysis of the western blots is represented as the mean band density normalized to lamin A/C. Values are the means ± SEM (n = 3). Means designated with the same letter are not significantly different. In A, the fluorescence intensity profile across a transverse section of one cell indicated in the second column is shown in the fourth column
Fig. 4 Inhibition of LPS-induced p65 translocation by synaptamide. BV2 murine microglia cells were incubated with LPS (100 ng/mL) with or without synaptamide (10 nM) and OEA (10 nM) for 30 min. Adenylyl cyclase inhibitor (SQ 22536, 10 μM) and PKA inhibitor (H-89, 10 μM) were added 30 min prior to LPS/synaptamide treatment. Translocation of p65 was determined by immunocytochemistry (red, Alexa Fluor 588; blue, DAPI) (a). Nuclear levels of p65 were determined by immunoblot analysis. α-Tublin and lamin A/C were used as internal controls for cytosolic and nuclear fractions (b). Densitometric analysis of the western blots is represented as the mean band density normalized to lamin A/C. Values are the means ± SEM (n = 3). Means designated with the same letter are not significantly different. In A, the fluorescence intensity profile across a transverse section of one cell indicated in the second column is shown in the fourth columnCC BY · PubMed Central
Fig. 5 In vivo effect of synaptamide on proinflammatory responses in LPS-challenged mice. The time course of the exogenous synaptamide was determined by injecting 5 mg/kg (i.p.) d4-synaptamide into C57BL/6 mice (n = 3 for each time point), and brains were collected at indicated time points for LC/MS analysis (a). C57BL/6 mice (n = 3 for each group) were treated with synaptamide (5 mg/kg, i.p.) following LPS injection (1 mg/kg, i.p.), and brains were collected at 2 h to determine LPS-induced gene expression by qPCR (b). Values are presented as mean ± SEM from four mice. Means designated with the same letter are not significantly different
Fig. 5 In vivo effect of synaptamide on proinflammatory responses in LPS-challenged mice. The time course of the exogenous synaptamide was determined by injecting 5 mg/kg (i.p.) d4-synaptamide into C57BL/6 mice (n = 3 for each time point), and brains were collected at indicated time points for LC/MS analysis (a). C57BL/6 mice (n = 3 for each group) were treated with synaptamide (5 mg/kg, i.p.) following LPS injection (1 mg/kg, i.p.), and brains were collected at 2 h to determine LPS-induced gene expression by qPCR (b). Values are presented as mean ± SEM from four mice. Means designated with the same letter are not significantly differentCC BY · PubMed Central
Fig. 6 Activation of microglia suppressed by synaptamide in the LPS-challenged mouse brain. Brain sections (30-μm thick) were prepared 24 h after LPS and/or synaptamide injection, and immunostaining for Iba-1 and GFAP was performed. Iba-1 (a) and GFAP (c) images from whole sections (top panel) and higher magnification of the rectangular area (×20, bottom panel) in the cerebral cortex (CX) and corpus callosum (CC) are presented, along with quantification results of Iba-1 (b) and GFAP (c). The Iba-1 and GFAP protein levels are shown by the western blot analysis of the whole brain extract (d). Values are presented as mean ± SEM from four mice. Means designated with the same letter are not significantly different. Scale bar: 100 μm (a, c)
Fig. 6 Activation of microglia suppressed by synaptamide in the LPS-challenged mouse brain. Brain sections (30-μm thick) were prepared 24 h after LPS and/or synaptamide injection, and immunostaining for Iba-1 and GFAP was performed. Iba-1 (a) and GFAP (c) images from whole sections (top panel) and higher magnification of the rectangular area (×20, bottom panel) in the cerebral cortex (CX) and corpus callosum (CC) are presented, along with quantification results of Iba-1 (b) and GFAP (c). The Iba-1 and GFAP protein levels are shown by the western blot analysis of the whole brain extract (d). Values are presented as mean ± SEM from four mice. Means designated with the same letter are not significantly different. Scale bar: 100 μm (a, c)CC BY · PubMed Central
Fig. 7 Suppression of proinflammatory responses by synaptamide in FAAH KO mice. Synaptamide levels in the FAAH KO mouse brains were quantified by mass spectrometry at 1 h after injection (i.p.) of 2 mg/kg synaptamide (a). The cytokine/chemokine expression in the brain was determined by qPCR at 2 h after injection of 1 mg/kg LPS followed by 2 mg/kg synaptamide (b). Values are presented as mean ± SEM from four mice. Means with the same letter are not significantly different
Fig. 7 Suppression of proinflammatory responses by synaptamide in FAAH KO mice. Synaptamide levels in the FAAH KO mouse brains were quantified by mass spectrometry at 1 h after injection (i.p.) of 2 mg/kg synaptamide (a). The cytokine/chemokine expression in the brain was determined by qPCR at 2 h after injection of 1 mg/kg LPS followed by 2 mg/kg synaptamide (b). Values are presented as mean ± SEM from four mice. Means with the same letter are not significantly differentCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 54 · Cited by 131

Metadata

Authors
Park, T., Chen, H., Kevala, K., Lee, J.-W., & Kim, H.-Y.
Affiliations
National Institutes of Health (US)
Corresponding author
Kim, Hee-Yong
Venue
Journal of Neuroinflammation
Published
2016-11-04
Volume
13
Issue
1
Pages
284-284
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2547349119
Cited by
131
References
54
Citations by year
2026: 6 · 2025: 13 · 2024: 7 · 2023: 24 · 2022: 9 · 2021: 23 · 2020: 15 · 2019: 17 · 2018: 9 · 2017: 8
FWCI
6.21
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Institute on Alcohol Abuse and Alcoholism (Intramural program)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Keywords
docosahexaenoic acid metabolites, neuroinflammation, lipopolysaccharide, microglial activation, astrocyte activation, cAMP/PKA signaling, CREB, p65 nuclear translocation, TNF-α, inducible nitric oxide synthase, anti-inflammatory activity
MeSH terms
Fatty Acid Amide Hydrolases, Cyclic AMP, Amidohydrolases, Animals, Animals, Newborn, Brain, Cells, Cultured, Enzyme Inhibitors, Fatty Acids, Lipopolysaccharides, Mice, Inbred C57BL, Signal Transduction, Cytokines, Rats, Wistar, Microglia, Cyclic AMP-Dependent Protein Kinases, Mice, Knockout, Mice, Rats, Nitric Oxide Synthase Type II, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. https://app.cochat.ai/papers/10.1186/s12974-016-0751-z
The paper
Park, T., Chen, H., Kevala, K., Lee, J.-W., & Kim, H.-Y. (2016). N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-016-0751-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.